Physician profile
Rebeca M Sharp
NPI 1962407353
$9,047.63
in general payments reported to CMS, 2019-2025
54 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $829 · 2021: $1,165 · 2022: $1,218 · 2023: $1,472 · 2024: $1,565 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,262 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,261.51 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $963.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $916.36 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $837.79 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $771.41 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $613.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $538.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $356.92 | 2019-2022 | |
| Amgen INC. | $351.76 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $340.40 | 2021-2025 | |
| Pfizer INC. | $326.21 | 2019-2025 | |
| Astellas Pharma US INC | $263.76 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.87 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $249.60 | 2019-2024 | Trintellix |
| Allergan, INC. | $226.34 | 2019-2020 | |
| Abbott Laboratories | $216.22 | 2019-2025 | Freestyle Libre 3 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebeca Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.